



ImmunoCellular  
Investor Relations Department  
23622 Calabasas Road  
Suite 300  
Calabasas, CA 91302  
United States

[Visit IR website](#)

#### AMEX: IMUC

Last Trade:	1.16
Trade Time:	3:50 PM ET May 26, 2017
Change:	0.02 <span style="color: green;">▲</span> (1.754%)
Day Range	1.12 - 1.20
52-Week Range	1.12 - 11.96
Volume	5,856

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company's lead product candidate, ICT-107, is a patient-specific, dendritic cell-based immunotherapy targeting glioblastoma and is currently being studied in an international Phase 3 trial. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy ta... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 15, 2017*  
[ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results](#)
- March 23, 2017*  
[ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology Collaboration](#)
- March 14, 2017*  
[ImmunoCellular Therapeutics Receives Audit Opinion With Going Concern Explanation](#)
- March 9, 2017*  
[ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update](#)
- March 6, 2017*  
[ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017](#)

## Financials [\[ View all \]](#)

- March 9, 2017*  
[Annual Report \(10-K\)](#)
- April 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 15, 2017*  
[Quarterly Report \(10-Q\)](#)
- November 10, 2016*  
[Quarterly Report \(10-Q\)](#)